{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:55:33Z","timestamp":1788195333074,"version":"build-2803163510"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13181-021-00835-6","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T20:02:29Z","timestamp":1617652949000},"page":"43-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-1233","authenticated-orcid":false,"given":"Neeraj","family":"Chhabra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"835_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/1744666X.2017.1366315","volume":"13","author":"H Yousefi","year":"2017","unstructured":"Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age. Expert Rev Clin Immunol. 2017;13:1001\u201315. https:\/\/doi.org\/10.1080\/1744666X.2017.1366315.","journal-title":"Expert Rev Clin Immunol"},{"key":"835_CR2","unstructured":"A review of cancer immunotherapy toxicity: Immune checkpoint inhibitors. J Med Toxicol n.d.;submitted for publication."},{"key":"835_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Rivi\u00e8re I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6 \/CD28 receptor. Nat Biotechnol. 2002;20:70\u20135. https:\/\/doi.org\/10.1038\/nbt0102-70.","journal-title":"Nat Biotechnol"},{"key":"835_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"key":"835_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape. Virchows Arch Int J Pathol. 2019;474:449\u201361. https:\/\/doi.org\/10.1007\/s00428-018-2484-0.","journal-title":"Virchows Arch Int J Pathol"},{"key":"835_CR6","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","volume":"318","author":"PB Bach","year":"2017","unstructured":"Bach PB, Giralt SA, Saltz LB. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. JAMA. 2017;318:1861\u20132. https:\/\/doi.org\/10.1001\/jama.2017.15218.","journal-title":"JAMA"},{"key":"835_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355. https:\/\/doi.org\/10.1016\/j.blre.2018.11.002.","journal-title":"Blood Rev"},{"key":"835_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072","volume":"3","author":"GH Lyman","year":"2020","unstructured":"Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. JAMA Netw Open. 2020;3:e202072. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2072.","journal-title":"JAMA Netw Open"},{"key":"835_CR9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP n.d. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50 (accessed January 19, 2021)."},{"key":"835_CR10","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415.","journal-title":"Sci Transl Med"},{"key":"835_CR11","unstructured":"Howard SC, Jones DP, Pui C-H. The Tumor Lysis Syndrome. Https:\/\/DoiOrg\/101056\/NEJMra0904569 2011. 10.1056\/NEJMra0904569."},{"key":"835_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol OncolJ Hematol Oncol. 2016;9:70. https:\/\/doi.org\/10.1186\/s13045-016-0299-5.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"835_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"835_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Mol Ther. 2010;18:843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"key":"835_CR15","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321\u201330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751.","journal-title":"Blood"},{"key":"835_CR16","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. J Immunol Res. 2018;2018:2386187\u201310. https:\/\/doi.org\/10.1155\/2018\/2386187.","journal-title":"J Immunol Res"},{"key":"835_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.950","volume":"103","author":"CE Annesley","year":"2018","unstructured":"Annesley CE, Summers C, Ceppi F, Gardner RA. The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2018;103:591\u20138. https:\/\/doi.org\/10.1002\/cpt.950.","journal-title":"Clin Pharmacol Ther"},{"key":"835_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.humimm.2019.01.011","volume":"80","author":"KD Wyatt","year":"2019","unstructured":"Wyatt KD, Bram RJ. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia. Hum Immunol. 2019;80:400\u20138. https:\/\/doi.org\/10.1016\/j.humimm.2019.01.011.","journal-title":"Hum Immunol"},{"key":"835_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"835_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1158\/2159-8290.CD-NB2017-169","volume":"8","author":"Research AA for C","year":"2018","unstructured":"Research AA for C. JCAR015 in ALL: A Root-Cause Investigation. Cancer Discov. 2018;8:4\u20135. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2017-169.","journal-title":"Cancer Discov"},{"key":"835_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","volume":"21","author":"F Kroschinsky","year":"2017","unstructured":"Kroschinsky F, St\u00f6lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care Lond Engl. 2017;21:89. https:\/\/doi.org\/10.1186\/s13054-017-1678-1.","journal-title":"Crit Care Lond Engl"},{"key":"835_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","volume":"11","author":"TC Gangadhar","year":"2014","unstructured":"Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014;11:91\u20139. https:\/\/doi.org\/10.1038\/nrclinonc.2013.245.","journal-title":"Nat Rev Clin Oncol"},{"key":"835_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. The Oncologist. 2018;23:943\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028.","journal-title":"The Oncologist"},{"key":"835_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4137\/CMAMD.S4864","volume":"3","author":"G Jones","year":"2010","unstructured":"Jones G, Ding C. Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81\u20139. https:\/\/doi.org\/10.4137\/CMAMD.S4864.","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"835_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study. JACC CardioOncology. 2020;2:193\u2013203. https:\/\/doi.org\/10.1016\/j.jaccao.2020.04.012.","journal-title":"JACC CardioOncology"},{"key":"835_CR26","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","volume":"74","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, et al. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. J Am Coll Cardiol. 2019;74:3153\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.049.","journal-title":"J Am Coll Cardiol"},{"key":"835_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863\u201371. https:\/\/doi.org\/10.1182\/blood-2013-03-490565.","journal-title":"Blood"},{"key":"835_CR28","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-Derived HLA-A1\u2013Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3\u2013Directed T Cells. Sci Transl Med. 2013;5:197ra103. https:\/\/doi.org\/10.1126\/scitranslmed.3006034.","journal-title":"Sci Transl Med"},{"key":"835_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther J Am Soc Gene Ther. 2011;19:620\u20136. https:\/\/doi.org\/10.1038\/mt.2010.272.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"835_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/COC.0000000000000596","volume":"42","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, et al. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol. 2019;42:789\u201396. https:\/\/doi.org\/10.1097\/COC.0000000000000596.","journal-title":"Am J Clin Oncol"},{"key":"835_CR31","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CHJ Lamers","year":"2006","unstructured":"Lamers CHJ, Sleijfer S, Vulto AG, Kruit WHJ, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:e20\u20132. https:\/\/doi.org\/10.1200\/JCO.2006.05.9964.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"835_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther J Am Soc Gene Ther. 2013;21:904\u201312. https:\/\/doi.org\/10.1038\/mt.2013.17.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"835_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"36","key":"835_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"2013","author":"RA Morgan","year":"1997","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga DD, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother Hagerstown Md. 1997;2013(36):133\u201351. https:\/\/doi.org\/10.1097\/CJI.0b013e3182829903.","journal-title":"J Immunother Hagerstown Md"},{"key":"835_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","volume":"21","author":"J Rice","year":"2019","unstructured":"Rice J, Nagle S, Randall J, Hinson HE. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Curr Treat Options Neurol. 2019;21:40. https:\/\/doi.org\/10.1007\/s11940-019-0580-3.","journal-title":"Curr Treat Options Neurol"},{"key":"835_CR36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.14680","volume":"181","author":"H Mei","year":"2018","unstructured":"Mei H, Jiang H, Wu Y, Guo T, Xia L, Jin R, et al. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. Br J Haematol. 2018;181:689\u201392. https:\/\/doi.org\/10.1111\/bjh.14680.","journal-title":"Br J Haematol"},{"key":"835_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.blre.2014.09.012","volume":"29","author":"RS Magge","year":"2015","unstructured":"Magge RS, DeAngelis LM. The double-edged sword: Neurotoxicity of chemotherapy. Blood Rev. 2015;29:93\u2013100. https:\/\/doi.org\/10.1016\/j.blre.2014.09.012.","journal-title":"Blood Rev"},{"key":"835_CR38","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.transproceed.2009.01.041","volume":"41","author":"A Dzudie","year":"2009","unstructured":"Dzudie A, Boissonnat P, Roussoulieres A, Cakmak MK, Bejui FT, et al. Cyclosporine-Related Posterior Reversible Encephalopathy Syndrome After Heart Transplantation: Should We Withdraw or Reduce Cyclosporine?: Case Reports. Transplant Proc. 2009;41:716\u201320. https:\/\/doi.org\/10.1016\/j.transproceed.2009.01.041.","journal-title":"Transplant Proc"},{"key":"835_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"key":"835_CR40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.2215\/CJN.12871117","volume":"13","author":"KD Jhaveri","year":"2018","unstructured":"Jhaveri KD, Rosner MH. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know. Clin J Am Soc Nephrol CJASN. 2018;13:796\u20138. https:\/\/doi.org\/10.2215\/CJN.12871117.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"835_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"key":"835_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","volume":"76","author":"S Gupta","year":"2020","unstructured":"Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O\u2019Donnell EK, Jacobson CA, et al. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020;76:63\u201371. https:\/\/doi.org\/10.1053\/j.ajkd.2019.10.011.","journal-title":"Am J Kidney Dis"},{"key":"835_CR43","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","volume":"26","author":"V Gutgarts","year":"2020","unstructured":"Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, et al. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biol Blood Marrow Transplant. 2020;26:1071\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.012.","journal-title":"Biol Blood Marrow Transplant"},{"key":"835_CR44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535\u201346. https:\/\/doi.org\/10.1182\/blood-2009-03-211714.","journal-title":"Blood"},{"key":"835_CR45","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2016.06.062","volume":"75","author":"CB Rubin","year":"2016","unstructured":"Rubin CB, Elenitsas R, Taylor L, Lacey SF, Kulikovskaya I, Gupta M, et al. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. J Am Acad Dermatol. 2016;75:1054\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2016.06.062.","journal-title":"J Am Acad Dermatol"},{"key":"835_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11899-010-0045-y","volume":"5","author":"M Agrawal","year":"2010","unstructured":"Agrawal M, Garg RJ, Cortes J, Quint\u00e1s-Cardama A. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep. 2010;5:70\u201380. https:\/\/doi.org\/10.1007\/s11899-010-0045-y.","journal-title":"Curr Hematol Malig Rep"},{"key":"835_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48. https:\/\/doi.org\/10.1186\/s12943-018-0804-2.","journal-title":"Mol Cancer"},{"key":"835_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11912-016-0514-0","volume":"18","author":"J Herrmann","year":"2016","unstructured":"Herrmann J. Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System? Curr Oncol Rep. 2016;18:33. https:\/\/doi.org\/10.1007\/s11912-016-0514-0.","journal-title":"Curr Oncol Rep"},{"key":"835_CR49","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol Stockh Swed. 2009;48:964\u201370. https:\/\/doi.org\/10.1080\/02841860903229124.","journal-title":"Acta Oncol Stockh Swed"},{"key":"835_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","volume":"40","author":"A Manouchehri","year":"2020","unstructured":"Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J. Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care. Arterioscler Thromb Vasc Biol. 2020;40:301\u20138. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313353.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"835_CR51","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128\u201337. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.079921.","journal-title":"Circulation"},{"key":"835_CR52","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316\u201321. https:\/\/doi.org\/10.1038\/leu.2013.70.","journal-title":"Leukemia"},{"key":"835_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030353","volume":"7","author":"J Zang","year":"2012","unstructured":"Zang J, Wu S, Tang L, Xu X, Bai J, Ding C, et al. Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis. PLOS ONE. 2012;7:e30353. https:\/\/doi.org\/10.1371\/journal.pone.0030353.","journal-title":"PLOS ONE"},{"key":"835_CR54","doi-asserted-by":"publisher","unstructured":"Porta-S\u00e1nchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017;6. https:\/\/doi.org\/10.1161\/JAHA.117.007724.","DOI":"10.1161\/JAHA.117.007724"},{"key":"835_CR55","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/OTT.S170138","volume":"11","author":"M Chaar","year":"2018","unstructured":"Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors\u2013associated cardiovascular toxicities. OncoTargets Ther. 2018;11:6227\u201337. https:\/\/doi.org\/10.2147\/OTT.S170138.","journal-title":"OncoTargets Ther"},{"key":"835_CR56","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet Lond Engl. 2007;370:2011\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(07)61865-0.","journal-title":"Lancet Lond Engl"},{"key":"835_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jjco\/hyv207","volume":"46","author":"T Kozuki","year":"2016","unstructured":"Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46:291\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyv207.","journal-title":"Jpn J Clin Oncol"},{"key":"835_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol. 2018;19:31\u20139. https:\/\/doi.org\/10.1007\/s40257-018-0384-3.","journal-title":"Am J Clin Dermatol"},{"key":"835_CR59","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1200\/jco.2014.32.15_suppl.8041","volume":"32","author":"N Katakami","year":"2014","unstructured":"Katakami N, Morita S, Yoshioka H, Seto T, Urata Y, Satouchi M, et al. Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L. J Clin Oncol. 2014;32:8041. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.8041.","journal-title":"J Clin Oncol"},{"key":"835_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2019.05.015","volume":"141","author":"A Jannin","year":"2019","unstructured":"Jannin A, Penel N, Ladsous M, Vantyghem MC, Do CC. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit Rev Oncol Hematol. 2019;141:23\u201335. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.05.015.","journal-title":"Crit Rev Oncol Hematol"},{"key":"835_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-08-0648","volume":"160","author":"F Illouz","year":"2009","unstructured":"Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol. 2009;160:331\u20136. https:\/\/doi.org\/10.1530\/EJE-08-0648.","journal-title":"Eur J Endocrinol"},{"key":"835_CR62","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11523-011-0197-2","volume":"6","author":"RL Brown","year":"2011","unstructured":"Brown RL. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Target Oncol. 2011;6:217\u201326. https:\/\/doi.org\/10.1007\/s11523-011-0197-2.","journal-title":"Target Oncol"},{"key":"835_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1758834009355164","volume":"2","author":"A Stein","year":"2010","unstructured":"Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2:51\u201363. https:\/\/doi.org\/10.1177\/1758834009355164.","journal-title":"Ther Adv Med Oncol"},{"key":"835_CR64","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/CMAR.S164535","volume":"10","author":"Y Que","year":"2018","unstructured":"Que Y, Liang Y, Zhao J, Ding Y, Peng R, Guan Y, et al. Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis. Cancer Manag Res. 2018;10:2141\u201350. https:\/\/doi.org\/10.2147\/CMAR.S164535.","journal-title":"Cancer Manag Res"},{"key":"835_CR65","doi-asserted-by":"publisher","first-page":"153473542092849","DOI":"10.1177\/1534735420928493","volume":"19","author":"KR Secombe","year":"2020","unstructured":"Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ, Bowen JM. Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. Integr Cancer Ther. 2020;19:1534735420928493. https:\/\/doi.org\/10.1177\/1534735420928493.","journal-title":"Integr Cancer Ther"},{"key":"835_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2009\/567486","volume":"2009","author":"A Harandi","year":"2009","unstructured":"Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. J Oncol. 2009;2009:1\u201314. https:\/\/doi.org\/10.1155\/2009\/567486.","journal-title":"J Oncol"},{"key":"835_CR67","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/era.13.31","volume":"13","author":"JC-H Yang","year":"2013","unstructured":"Yang JC-H, Reguart N, Barinoff J, K\u00f6hler J, Uttenreuther-Fischer M, Stammberger U, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13:729\u201336. https:\/\/doi.org\/10.1586\/era.13.31.","journal-title":"Expert Rev Anticancer Ther"},{"key":"835_CR68","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","volume":"75","author":"R Califano","year":"2015","unstructured":"Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, et al. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs. 2015;75:1335\u201348. https:\/\/doi.org\/10.1007\/s40265-015-0434-6.","journal-title":"Drugs"},{"key":"835_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13256-018-1588-0","volume":"12","author":"LS Nacif","year":"2018","unstructured":"Nacif LS, Waisberg DR, Pinheiro RS, Lima FR, Rocha-Santos V, Andraus W, et al. Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. J Med Case Reports. 2018;12:63. https:\/\/doi.org\/10.1186\/s13256-018-1588-0.","journal-title":"J Med Case Reports"},{"key":"835_CR70","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.2147\/CMAR.S237968","volume":"12","author":"J Qian","year":"2020","unstructured":"Qian J, Zhang X, Zhang B, Yan B, Wang L, Gu P, et al. Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study. Cancer Manag Res. 2020;12:3293\u20139. https:\/\/doi.org\/10.2147\/CMAR.S237968.","journal-title":"Cancer Manag Res"},{"key":"835_CR71","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36:491\u2013503. https:\/\/doi.org\/10.1007\/s40264-013-0048-4.","journal-title":"Drug Saf"},{"key":"835_CR72","unstructured":"Practical management of tyrosine kinase inhibitor-associated side effects in GIST- ClinicalKey n.d. https:\/\/www-clinicalkey-com.ezproxy.rush.edu\/#!\/content\/playContent\/1-s2.0-S0305737210000861?scrollTo=%23bib76 (accessed January 29, 2021)."},{"key":"835_CR73","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","volume":"27","author":"O Tonyali","year":"2010","unstructured":"Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, et al. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol. 2010;27:768\u201373. https:\/\/doi.org\/10.1007\/s12032-009-9284-y.","journal-title":"Med Oncol"},{"key":"835_CR74","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ajh.23442","volume":"88","author":"EA Coon","year":"2013","unstructured":"Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol. 2013;88:534\u20135. https:\/\/doi.org\/10.1002\/ajh.23442.","journal-title":"Am J Hematol"},{"key":"835_CR75","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3324\/haematol.2015.129221","volume":"100","author":"G Gugliotta","year":"2015","unstructured":"Gugliotta G, Castagnetti F, Breccia M, Levato L, D\u2019Adda M, Stagno F, et al. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica. 2015;100:1146\u201350. https:\/\/doi.org\/10.3324\/haematol.2015.129221.","journal-title":"Haematologica"},{"key":"835_CR76","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1056\/NEJMra1012354","volume":"364","author":"VC Sheffield","year":"2011","unstructured":"Sheffield VC, Stone EM. Genomics and the eye. N Engl J Med. 2011;364:1932\u201342. https:\/\/doi.org\/10.1056\/NEJMra1012354.","journal-title":"N Engl J Med"},{"key":"835_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1188\/16.ONF.235-243","volume":"43","author":"ME Davis","year":"2016","unstructured":"Davis ME. Ocular Toxicity of Tyrosine Kinase Inhibitors. Oncol Nurs Forum. 2016;43:235\u201343. https:\/\/doi.org\/10.1188\/16.ONF.235-243.","journal-title":"Oncol Nurs Forum"},{"key":"835_CR78","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/DER.0b013e31826e45d7","volume":"23","author":"G Fabbrocini","year":"2012","unstructured":"Fabbrocini G, Panariello L, Cacciapuoti S, Bianca D, Ayala F. Trichomegaly of the Eyelashes During Therapy With Epidermal Growth Factor Receptor Inhibitors: Report of 3 Cases. Dermatitis. 2012;23:237\u20138.","journal-title":"Dermatitis"},{"key":"835_CR79","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","volume":"39","author":"S M\u00e9ndez-Mart\u00ednez","year":"2019","unstructured":"M\u00e9ndez-Mart\u00ednez S, Calvo P, Ruiz-Moreno O, Pardi\u00f1as Bar\u00f3n N, Leci\u00f1ena Bueno J, Gil Ruiz MDR, et al. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina Phila Pa. 2019;39:1435\u201350. https:\/\/doi.org\/10.1097\/IAE.0000000000002451.","journal-title":"Retina Phila Pa"},{"key":"835_CR80","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12886-017-0541-0","volume":"17","author":"S Sarny","year":"2017","unstructured":"Sarny S, Neumayer M, Kofler J, El-Shabrawi Y. Ocular toxicity due to Trametinib and Dabrafenib. BMC Ophthalmol. 2017;17:146. https:\/\/doi.org\/10.1186\/s12886-017-0541-0.","journal-title":"BMC Ophthalmol"},{"key":"835_CR81","first-page":"2199","volume":"70","author":"S Akiyama","year":"2012","unstructured":"Akiyama S. Specific adverse events caused by monoclonal antibodies, focusing on the prophylaxis and management. Nihon Rinsho Jpn J Clin Med. 2012;70:2199\u2013204.","journal-title":"Nihon Rinsho Jpn J Clin Med"},{"key":"835_CR82","doi-asserted-by":"publisher","first-page":"e26333","DOI":"10.4161\/onci.26333","volume":"2","author":"BA Baldo","year":"2013","unstructured":"Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy. Oncoimmunology. 2013;2:e26333. https:\/\/doi.org\/10.4161\/onci.26333.","journal-title":"Oncoimmunology"},{"key":"835_CR83","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10555-013-9447-3","volume":"32","author":"BA Baldo","year":"2013","unstructured":"Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev. 2013;32:723\u201361. https:\/\/doi.org\/10.1007\/s10555-013-9447-3.","journal-title":"Cancer Metastasis Rev"},{"key":"835_CR84","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1023\/a:1006341717398","volume":"18","author":"RO Dillman","year":"1999","unstructured":"Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18:465\u201371. https:\/\/doi.org\/10.1023\/a:1006341717398.","journal-title":"Cancer Metastasis Rev"},{"key":"835_CR85","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. The Oncologist. 2008;13:725\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2008-0012.","journal-title":"The Oncologist"},{"key":"835_CR86","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"H-J Lenz","year":"2007","unstructured":"Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. The Oncologist. 2007;12:601\u20139. https:\/\/doi.org\/10.1634\/theoncologist.12-5-601.","journal-title":"The Oncologist"},{"key":"835_CR87","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.iac.2015.01.011","volume":"35","author":"MC Castells","year":"2015","unstructured":"Castells MC. Anaphylaxis to chemotherapy and monoclonal antibodies. Immunol Allergy Clin North Am. 2015;35:335\u201348. https:\/\/doi.org\/10.1016\/j.iac.2015.01.011.","journal-title":"Immunol Allergy Clin North Am"},{"key":"835_CR88","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4065\/83.2.197","volume":"83","author":"PP Sengupta","year":"2008","unstructured":"Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc. 2008;83:197\u2013203. https:\/\/doi.org\/10.4065\/83.2.197.","journal-title":"Mayo Clin Proc"},{"key":"835_CR89","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","volume":"99","author":"A Farolfi","year":"2013","unstructured":"Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart Br Card Soc. 2013;99:634\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2012-303151.","journal-title":"Heart Br Card Soc"},{"key":"835_CR90","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","volume":"53","author":"G Curigliano","year":"2010","unstructured":"Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Prog Cardiovasc Dis. 2010;53:94\u2013104. https:\/\/doi.org\/10.1016\/j.pcad.2010.05.006.","journal-title":"Prog Cardiovasc Dis"},{"key":"835_CR91","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2217\/fca.11.54","volume":"7","author":"A Albini","year":"2011","unstructured":"Albini A, Cesana E, Donatelli F, Cammarota R, Bucci EO, Baravelli M, et al. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol. 2011;7:693\u2013704. https:\/\/doi.org\/10.2217\/fca.11.54.","journal-title":"Future Cardiol"},{"key":"835_CR92","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMc1215887","volume":"368","author":"GM Cote","year":"2013","unstructured":"Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med. 2013;368:876. https:\/\/doi.org\/10.1056\/NEJMc1215887.","journal-title":"N Engl J Med"},{"key":"835_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/abt\/tby003","volume":"1","author":"N Mohan","year":"2018","unstructured":"Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018;1:13\u20137. https:\/\/doi.org\/10.1093\/abt\/tby003.","journal-title":"Antib Ther"},{"key":"835_CR94","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11886-019-1121-0","volume":"21","author":"P Menna","year":"2019","unstructured":"Menna P, Minotti G, Salvatorelli E. Cardiotoxicity of Targeted Cancer Drugs: Concerns, \u201cThe Cart Before the Horse,\u201d and Lessons from Trastuzumab. Curr Cardiol Rep. 2019;21:33. https:\/\/doi.org\/10.1007\/s11886-019-1121-0.","journal-title":"Curr Cardiol Rep"},{"key":"835_CR95","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccl.2019.07.005","volume":"37","author":"R Barish","year":"2019","unstructured":"Barish R, Gates E, Barac A. Trastuzumab-Induced Cardiomyopathy. Cardiol Clin. 2019;37:407\u201318. https:\/\/doi.org\/10.1016\/j.ccl.2019.07.005.","journal-title":"Cardiol Clin"},{"key":"835_CR96","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175:595\u2013603. https:\/\/doi.org\/10.1007\/s10549-019-05191-2.","journal-title":"Breast Cancer Res Treat"},{"key":"835_CR97","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/CMAR.S163391","volume":"10","author":"C-B Chen","year":"2018","unstructured":"Chen C-B, Wu M-Y, Ng CY, Lu C-W, Wu J, Kao P-H, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259\u201373. https:\/\/doi.org\/10.2147\/CMAR.S163391.","journal-title":"Cancer Manag Res"},{"key":"835_CR98","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2146\/ajhp080455","volume":"66","author":"SS Shord","year":"2009","unstructured":"Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2009;66:999\u20131013. https:\/\/doi.org\/10.2146\/ajhp080455.","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"key":"835_CR99","first-page":"437","volume":"111","author":"S Sliesoraitis","year":"2011","unstructured":"Sliesoraitis S, Tawfik B. Bevacizumab-induced bowel perforation. J Am Osteopath Assoc. 2011;111:437\u201341.","journal-title":"J Am Osteopath Assoc"},{"key":"835_CR100","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdr432","volume":"23","author":"J Cortes","year":"2012","unstructured":"Cortes J, Calvo V, Ram\u00edrez-Merino N, O\u2019Shaughnessy J, Brufsky A, Robert N, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol Off J Eur Soc Med Oncol. 2012;23:1130\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdr432.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"835_CR101","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF Inhibition and Renal Thrombotic Microangiopathy. N Engl J Med. 2008;358:1129\u201336. https:\/\/doi.org\/10.1056\/NEJMoa0707330.","journal-title":"N Engl J Med"},{"key":"835_CR102","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","volume":"51","author":"AV Hadjinicolaou","year":"2012","unstructured":"Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ost\u00f6r AJK. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatol Oxf Engl. 2012;51:653\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/ker290.","journal-title":"Rheumatol Oxf Engl"},{"key":"835_CR103","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1183\/09031936.00080209","volume":"35","author":"H Liot\u00e9","year":"2010","unstructured":"Liot\u00e9 H, Liot\u00e9 F, S\u00e9roussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J. 2010;35:681\u20137. https:\/\/doi.org\/10.1183\/09031936.00080209.","journal-title":"Eur Respir J"},{"key":"835_CR104","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1053\/j.seminoncol.2006.01.027","volume":"33","author":"A Osterborg","year":"2006","unstructured":"Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab-related side effects. Semin Oncol. 2006;33:S29\u201335. https:\/\/doi.org\/10.1053\/j.seminoncol.2006.01.027.","journal-title":"Semin Oncol"},{"key":"835_CR105","doi-asserted-by":"publisher","unstructured":"Fouda GE, Bavbek S. Rituximab Hypersensitivity: From Clinical Presentation to Management. Front Pharmacol. 2020;11. https:\/\/doi.org\/10.3389\/fphar.2020.572863.","DOI":"10.3389\/fphar.2020.572863"},{"key":"835_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/428169","volume":"2015","author":"M Guan","year":"2015","unstructured":"Guan M, Zhou Y-P, Sun J-L, Chen S-C. Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Res Int. 2015;2015:1\u201313. https:\/\/doi.org\/10.1155\/2015\/428169.","journal-title":"BioMed Res Int"},{"key":"835_CR107","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/1060028017702654","volume":"51","author":"PA Corrigan","year":"2017","unstructured":"Corrigan PA, Beaulieu C, Patel RB, Lowe DK. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma. Ann Pharmacother. 2017;51:675\u201381. https:\/\/doi.org\/10.1177\/1060028017702654.","journal-title":"Ann Pharmacother"},{"key":"835_CR108","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler SE, Speranza M-C, Cho C-F, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2017;3:841\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2064.","journal-title":"JAMA Oncol"},{"key":"835_CR109","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/77558","volume":"6","author":"DF Stojdl","year":"2000","unstructured":"Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821\u20135. https:\/\/doi.org\/10.1038\/77558.","journal-title":"Nat Med"},{"key":"835_CR110","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","volume":"26","author":"D Mahalingam","year":"2020","unstructured":"Mahalingam D, Wilkinson GA, Eng KH, Fields P, Raber P, Moseley JL, et al. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:71\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2078.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"835_CR111","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1658\u201367. https:\/\/doi.org\/10.1200\/JCO.2017.73.7379.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"835_CR112","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2780\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"835_CR113","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ebiom.2019.07.066","volume":"47","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 2019;47:89\u201397. https:\/\/doi.org\/10.1016\/j.ebiom.2019.07.066.","journal-title":"EBioMedicine"},{"key":"835_CR114","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/CMR.0000000000000399","volume":"28","author":"J Chesney","year":"2018","unstructured":"Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, et al. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Melanoma Res. 2018;28:44\u201351. https:\/\/doi.org\/10.1097\/CMR.0000000000000399.","journal-title":"Melanoma Res"},{"key":"835_CR115","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","volume":"11","author":"PRA Buijs","year":"2015","unstructured":"Buijs PRA, Verhagen JHE, van Eijck CHJ, van den Hoogen BG. Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccines Immunother. 2015;11:1573\u201384. https:\/\/doi.org\/10.1080\/21645515.2015.1037058.","journal-title":"Hum Vaccines Immunother"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-021-00835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-021-00835-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-021-00835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:48:55Z","timestamp":1744188535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-021-00835-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1007\/s13181-021-00835-6","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"3 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}